Results 201 to 210 of about 914,661 (291)

Development and validation of the renal cancer scale among the system of quality of life instruments for cancer patients QLICP-RE (V2.0): a multicenter longitudinal study. [PDF]

BMC Nephrol
Xu C, Li C, Hu L, Guo S, Wu J, Zhang J, Guo F, Wan C.   +7 more
europepmc   +1 more source

TriCON: A Carbon‐Based Triple‐Modal Nanoplatform for Pancreatic Cancer Therapy

Advanced Science, EarlyView.
We developed TriCON, a triple‐modality nanotherapeutic platform, to treat pancreatic ductal adenocarcinoma (PDAC) by synergizing gene editing, chemotherapy, and immunotherapy. TriCON utilizes CRISPR/Cas9 to target the poliovirus receptor (PVR), combined with nano‐encapsulated doxorubicin and checkpoint blockade. This approach achieved significant tumor
Xinyu Peng, Jiaxing Huang, Shengnan Lv, Jian Zhang, Liangliang Zhang, Huan Liu, Yan Liu, Zhen‐An Qiao, Feng Wei, Bao‐Lian Su   +9 more
wiley   +1 more source

Perirenal fat thickness may be a significant predictor of prognosis and postoperative renal function in renal cancer surgery patients. [PDF]

Sci Rep
Tang H, Xie Y, Yang L, Zhang L, Fu Q, Huang Y, Huang T, Wen D, Ye B, Yang X, Zhang Z, Zhou F, Peng Y, Zhang W.   +13 more
europepmc   +1 more source

Metabolic Reprogramming of T Cells by Dual UCP2 and IL‐17 Blockade Enhances Immunity Against Pancreatic Cancer

Advanced Science, EarlyView.
This study demonstrates that dual UCP2/IL‐17 blockade reprograms T‐cell metabolism to overcome PDAC immunosuppression. Genipin‐mediated UCP2 inhibition enhances CD8⁺ T‐cell IFN‐γ via IL‐12R/STAT4/mTOR signaling and mitochondrial OXPHOS. Combined IL‐17 depletion amplifies Tc1/Th1 responses, reduces MDSCs, and prolongs survival in PDAC models ...
Chuan‐Teng Liu, Chun‐Chieh Yeh, Tsai‐Chen Wu, Chia‐Hsin Lin, Yi‐Ting Kuo, Yoichiro Iwakura, Yuan‐Ji Day, Charles Drake, Vedran Radojcic, Ying‐Chyi Song, Heng‐Hsiung Wu, Hung‐Rong Yen   +11 more
wiley   +1 more source

FABP4-mediated ERK phosphorylation promotes renal cancer cell migration. [PDF]

BMC Cancer
La Civita E, Sirica R, Crocetto F, Ferro M, Lasorsa F, Lucarelli G, Imbimbo C, Formisano P, Beguinot F, Terracciano D.   +9 more
europepmc   +1 more source

Ultrasound‐Boosted Liposomal Prodrug Overcomes Age‐Associated Biodistribution Disparity in Pediatric Solid Tumor Therapy

Advanced Science, EarlyView.
The age‐associated disparity of nanocarrier biodistribution limits the nanotherapeutics of childhood solid tumors. This study developed an ultrasound‐activated liposomal prodrug (CSCPTL) to overcome the age‐associated disparity of off‐target distribution.
Danfei Chen, Junjun Xu, Jian Chen, Jue Hu, Xiaobo Xuan, Haifang Cai, Mingdong Yang, Zhuxian Zhou, Guowei Wang   +8 more
wiley   +1 more source

Patients with Papillary Renal Cancer and Germline Duplication of <i>MET</i> Exons 5-21. [PDF]

Biomedicines
Mikhaylenko DS, Kuryakova NB, Bostanova FM, Zabnenkova VV, Ryzhkova OP, Volodin IV, Zaletaev DV, Pustoshilov DV, Kutsev SI, Strelnikov VV.   +9 more
europepmc   +1 more source

ERM Inhibition Confers Ferroptosis Resistance through ROS‐Induced NRF2 Signaling

Advanced Science, EarlyView.
ERM inhibition disrupts ERM‐actin interactions, elevating ROS and triggering KEAP1 degradation, which stabilizes and activates NRF2. Nuclear NRF2 induces cytoprotective genes, notably HMOX1, enhancing redox buffering and suppressing lipid peroxidation to resist erastin‐induced ferroptosis.
Menghao Qiao, Liqun Zhou, Minhua Zhou, Yu Fang, Haiying Mai, Lingbo Cao, Kun Xu, Yuan Sang, Minyi Chen, Jiewei Huang, Peiyi Huang, Zhipeng Yan, Chao Wang, Zhangshuai Dai, Dichun Huang, Ronghan He, Lijuan Pang, Yunmiao Guo, Ting Gang Chew, Junqi Huang   +19 more
wiley   +1 more source

HDAC7 promotes renal cancer progression by reprogramming branched-chain amino acid metabolism. [PDF]

Sci Adv
Nam H, Kundu A, Karki S, Kirkman RL, Chandrashekar DS, Foote JB, Zhang G, He W, Varambally S, Ding HF, Sudarshan S.   +10 more
europepmc   +1 more source

IL4I1⁺ Macrophages and TDO2⁺ Myofibroblasts Drive AhR‐Mediated Immunosuppression and Ferroptosis Resistance in Solid Predominant Lung Adenocarcinoma

Advanced Science, EarlyView.
Solid predominant lung adenocarcinoma exhibits an immune‐excluded, ferroptosis‐resistant niche enriched with IL4I1⁺ TAMs and TDO2⁺ myCAFs. Spatial and multi‐omics analyses reveal AhR‐driven crosstalk that promotes T cell exhaustion and therapy resistance. Blocking AhR with CH‐223191 restores ferroptosis sensitivity, and its combination with ferroptosis
Zhaoxuan Wang, Weijiao Xu, Lei Zhao, Lin Zhong, Wendan Yu, Shengmin Wang, Lu Sun, Tao Guo, Fengzhou Li, Zhuoshi Li, Lei Fang, Shiqing Wang, Guohui Zhang, Guoqing Xue, Wei Guo, Shilei Zhao, Chundong Gu   +16 more
wiley   +1 more source